VM — Voyageur Pharmaceuticals Share Price
Last trade - 00:00- CA$28.90m
- CA$28.77m
- 19
- 11
- 89
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 64.23 | ||
| Price to Tang. Book | 64.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -338.74% | ||
| Return on Equity | -181.07% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Nov | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Directors
- Brent Willis PRE
- Ron Love CFO
- Bradly Willis COO
- Trent Abraham IND
- Randy Henkle IND
- Merle Olson IND
- Ronald Sifton IND
- Last Annual
- November 30th, 2024
- Last Interim
- November 30th, 2024
- Incorporated
- July 23rd, 2008
- Public Since
- May 18th, 2012
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 160,552,850
- Address
- Dome Tower 800, 333 7 Ave. S.W., CALGARY, T2P 2Z1
- Web
- https://voyageurpharmaceuticals.ca/
- Phone
- +1 4039235944
- Auditors
- MNP LLP
Upcoming Events for VM
Similar to VM
Aequus Pharmaceuticals
TSX Venture Exchange
Arch Biopartners
TSX Venture Exchange
Biosyent
TSX Venture Exchange
Cytophage Technologies
TSX Venture Exchange
Decibel Cannabis
TSX Venture Exchange
FAQ
As of Today at 24:01 UTC, shares in Voyageur Pharmaceuticals are trading at CA$0.18. This share price information is delayed by 15 minutes.
Shares in Voyageur Pharmaceuticals last closed at CA$0.18 and the price had moved by +250% over the past 365 days. In terms of relative price strength the Voyageur Pharmaceuticals share price has outperformed the Toronto Stock Exchange 300 Composite Index by +211.17% over the past year.
The overall consensus recommendation for Voyageur Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreVoyageur Pharmaceuticals does not currently pay a dividend.
Voyageur Pharmaceuticals does not currently pay a dividend.
Voyageur Pharmaceuticals does not currently pay a dividend.
To buy shares in Voyageur Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.18, shares in Voyageur Pharmaceuticals had a market capitalisation of CA$28.90m.
Here are the trading details for Voyageur Pharmaceuticals:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: VM
Based on an overall assessment of its quality, value and momentum Voyageur Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Voyageur Pharmaceuticals is CA$0.55. That is 205.56% above the last closing price of CA$0.18.
Analysts covering Voyageur Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Voyageur Pharmaceuticals. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +148.53%.
As of the last closing price of CA$0.18, shares in Voyageur Pharmaceuticals were trading +75.65% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Voyageur Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Voyageur Pharmaceuticals' management team is headed by:
- Brent Willis - PRE
- Ron Love - CFO
- Bradly Willis - COO
- Trent Abraham - IND
- Randy Henkle - IND
- Merle Olson - IND
- Ronald Sifton - IND